Printer Friendly

IVAX' PHARMACEUTICAL SUBSIDIARY INITIATES UNITED STATES CLINICAL STUDIES FOR ALZENE(TM)

 IVAX' PHARMACEUTICAL SUBSIDIARY INITIATES UNITED STATES CLINICAL
 STUDIES FOR ALZENE(TM)
 MIAMI, Feb. 19 /PRNewswire/ -- IVAX Corporation (AMEX: IVX) announced today that its wholly owned subsidiary Baker Cummins Pharmaceuticals, Inc. is commencing Phase II clinical trials in the United States to study the effects of the drug Alzene(TM) in patients with Alzheimer's disease. The double blind placebo controlled studies will be conducted at two sites in the United States -- the Aging and Dementia Research Center of the New York University's Medical Center and the Miami Jewish Home and Hospital for the Aged.
 Alzene(TM) has been clinically studied in Israel by scientists and physicians associated with Bar Ilan University. These studies indicated that approximately 70 percent of the patients taking Alzene(TM) experienced a significant reduction in the signs and symptoms related to the disease.
 Alzheimer's disease is characterized by memory loss and the progressive degeneration of the central nervous system. While Alzheimer's disease affects over four million individuals in the United States alone and is the fourth leading cause of death in the United States, there is presently no effective treatment for the disease. Alzheimer's disease is associated with diminished neuronal cell membrane fluidity. The drug Alzene(TM) is believed to improve neuronal cell membrane fluidity by modifying the fatty acid composition of the neuronal cell membrane.
 IVAX Corporation is a holding company with subsidiaries involved in specialty chemicals, pharmaceuticals and medical diagnostics. IVAX' principal subsidiaries include Baker Cummins Pharmaceuticals, Inc., a developer and marketer of unique brand name pharmaceuticals; Norton Healthcare Limited, a leading manufacturer and marketer of off-patent pharmaceuticals in the United Kingdom, Ireland and other countries; Goldline Laboratories, Inc., a national marketer of off-patent prescription and over the counter pharmaceuticals in the United States; Best Generics, Inc., a national distributor of off-patent pharmaceuticals in the United States; Baker Cummins Dermatologicals, Inc., a dermatological products company; Diamedix Corporation, a medical diagnostics company; Delta Biologicals S.r.l., a marketer of medical diagnostic tests and instruments in Italy; and IVAX Industries, Inc., a chemical specialties business.
 -0- 1/31/92
 /CONTACT: Richard C. Pfenniger Jr., senior vice president of legal affairs of IVAX Corporation, 305-590-2309/
 (IVX) CO: IVAX Corporation ST: Florida IN: MTC SU:


SS-AW -- FL006 -- 0509 02/19/92 13:45 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 19, 1992
Words:376
Previous Article:SOUTHERN CALIFORNIA EDISON UNVEILS ADVANCED DIAGNOSTIC CONTROL SYSTEM AT EL SEGUNDO GENERATING PLANT
Next Article:KINNARD INVESTMENTS ANNOUNCES RECORD 1991 REVENUES AND EARNINGS
Topics:


Related Articles
BAKER CUMMINS PHARMACEUTICALS RECEIVES LICENSE TO CHEMOPROTECTIVE DRUG
IVAX' SUBSIDIARY RECEIVES APPROVAL TO SELL SODIUM CROMOGLYCATE METERED DOSE INHALER IN THE UNITED KINGDOM
NEW MEMBER APPOINTED TO IVAX BOARD OF DIRECTORS
IVAX ACQUIRES WILLEN DRUG COMPANY
IVAX ACQUIRES DVM PHARMACEUTICALS, INC.
BAKER CUMMINS PHARMACEUTICALS CHANGES ITS NAME TO BAKER NORTON PHARMACEUTICALS
IVAX ANNOUNCES STRATEGIC ALLIANCE WITH NAPRO BIOTHERAPEUTICS REGARDING TAXOL
IVAX Corporation And NaPro BioTherapeutics Announce Submission Of New Drug Application For Paclitaxel
Preclinical Studies Conducted With NIH Indicate IVAX' Elmiron(R) Holds Promise As a Treatment for Progressive Kidney Disease and Atherosclerosis
IVAX Commences Phase I Studies of Topical Drug For Erectile Dysfunction

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters